10 1.2.1 Description and Identification of Brachyury .......................................................... 10 1.2.2 Brachyury Function in Epithelial- to-Mesenchymal Transition (EMT) .................. 10 1.2.3 Analysis of Brachyury Expression in Human Tumors and Normal Tissues .......... 12 1.2.4 Brachyury Expression in Lung Carcinomas ........................................................... 14 1.2.5 Expression of Brachyury Protein in Breast Tumor Samples .................................. 16 1.2.6 Brachyury Expression and Prognosis ..................................................................... 17 1.2.7 Brachyury Confers Chemotherapy Resistance ....................................................... 18 1.2.8 Immunogenicity of the Brachyury Protein ............................................................. 19 1.2.9 Prior Human Expe rience with Brachyury Vaccine Therapy .................................. 19 1.2.10 Poxviral Vectors ...................................................................................................... 19 1.2.11 Safety of Poxviral Vectors ...................................................................................... 20 1.2.12 Modified vaccinia Ankara (MVA) .......................................................................... 21 1.2.13 Clinical Experience with MVA Vector -Based Trials ............................................. 21 1.2.14 Safety of Recombinant MVA Vectors .................................................................... 22 1.2.15 TRICOM Costimulatory Molecules ....................................................................... 23 1.2.16 MVA- TRICOM in CLL .......................................................................................... 23 1.2.17 Infection of Human Dendritic Cells with MVA -Brachyury -TRICOM .................. 24 1.2.18 Induction of Human T Cells by MVA- Brachyury -TRICOM ................................. 25 1.2.19 MVA- Brachyury -TRICOM -Infected Human DCs Stimulate Brachyury -Specific CD4+ T cells ......................................................................................................................... 26 1.2.20 MVA- Bavarian Nordic (MVA -BN) .......................................................................